Brexpiprazole Earns Top-Line Results From Two Phase Three Clinical Trails For Alzheimer’s-Type Dementia Treatment

Otsuka Pharmaceutical (Otsuka) and H. Lundbeck (Lundbeck) announced top-line results from two phase three clinical trials assessing the efficacy, safety and tolerability of brexpiprazole in the treatment of Alzheimer's-type dementia agitation. Both companies will meet with the FDA to discuss study results, and the results will be presented in scientific congresses over the next year.

Both trials were randomized, double-blind, placebo-controlled phase three studies that enrolled a combined total of approximately 700 participants aged 51 to 90 years of age with a diagnosis of probable Alzheimer’s disease and symptoms of agitation. One 12-week . . .